Supply Chain

This episode of Pharma Pulse covers the former CDC director’s claim she was dismissed for refusing to prioritize ideology over evidence, new findings that physician mental health remains a serious concern, and Eli Lilly’s $5 billion investment in a new Virginia manufacturing plant to expand biologics production.

The new Goochland County facility will serve as Lilly’s first fully integrated API and drug product site, focusing on antibody-drug conjugates, while creating thousands of jobs and strengthening domestic supply chains.

The collaboration seeks to reduce drug waste, prevent errors, and support more reliable delivery of life-saving therapies to patients worldwide.

This episode of Pharma Pulse covers new FDA guidance to speed development of non-opioid pain treatments, the FTC’s warning against non-compete agreements for doctors and nurses, and DHL Supply Chain’s acquisition of SDS Rx to strengthen last-mile healthcare delivery.

The deal will integrate SDS Rx’s specialized delivery network of US locations into DHL’s Life Sciences & Healthcare division, strengthening same-day and final-mile services as demand for specialty pharma and patient-centered logistics continues to rise.

This episode of Pharma Pulse covers reports of a White House executive order to restrict treatments discovered in China, new data showing robust immune responses from Pfizer and BioNTech’s COVID-19 vaccine in high-risk adults, and Samsung Biologics’ latest US manufacturing deal amid tariff uncertainty.

In the final part of his Pharma Commerce video interview, Boyede Sobitan, Zebra Technologies’ global healthcare strategy lead, details how in a post-COVID landscape, technologies that track and regionalize hospital inventory could become critical tools for state and local health departments, ensuring visibility, preparedness, and smarter resource allocation during future disruptions.

The South Korean CDMO has signed its second multi-billion-dollar contract in less than a year, even as shifting US trade policies and looming tariffs create challenges for global drugmakers.

In the third part of his Pharma Commerce video interview, Boyede Sobitan, Zebra Technologies’ global healthcare strategy lead, explains why forward-thinking facilities see these tools as key to cutting errors and improving inventory efficiency.

The move consolidates R&D, manufacturing, and commercialization under the CGM system’s developer to accelerate growth and expand global reach.

This episode of Pharma Pulse covers Gilead’s groundbreaking on a new technical development hub to accelerate biopharma innovation, the World Health Organization’s decision to add GLP-1s to its Essential Medicines List for diabetes, and new data showing high-dose influenza vaccines reduce heart risks in older adults.

The new 180,000-square-foot facility in Foster City anchors the company’s long-term $32 billion investment in domestic manufacturing and R&D.

This episode of Pharma Pulse covers President Trump’s appeal to the Supreme Court to preserve pharma tariffs, Sanofi’s 10% stock drop after Amlitelimab failed in Phase III, and new research showing how the COVID-19 pandemic reshaped pneumococcal mortality trends.

Following a federal appeals court decision that struck down much of his tariff authority under the International Emergency Economic Powers Act, President Trump is asking the Supreme Court to fast-track review.

The company is committing over half a billion dollars to build a state-of-the-art research hub in Thousand Oaks, CA, designed to accelerate next-generation therapeutics through advanced automation and collaboration.

Lilly has temporarily halted UK shipments of Mounjaro until Sept. 1, when new list prices take effect.

CCT is strengthening its Asia-Pacific footprint through new hubs in Tokyo and Mumbai, expanded distributor partnerships in China and Australia, and rebranded regional operations

FDA approves COVID-19 vaccines from Moderna, Pfizer-BioNTech, and Novavax targeting the LP.8.1 sublineage of SARS-CoV-2, with eligibility limited to adults aged 65 years and older and those with underlying medical conditions that place them with a high risk for severe disease.

As of today, Aug. 27, wholesale distributors must fully comply with the Drug Supply Chain Security Act’s enhanced drug distribution requirements, closing the FDA’s exemption period and advancing efforts to strengthen patient safety and supply chain integrity.

The merger integrates EVERSANA’s commercialization services with Waltz Health’s AI-powered payer tools to address patient affordability, streamline drug access, and reduce costs for high-expense therapies such as GLP-1s.

The new 700,000-square-foot Holly Springs site—part of Roche’s $50 billion US investment plan—will focus on metabolic and obesity treatments, create 400 jobs, and strengthen domestic biopharma manufacturing amid shifting tariff and drug pricing policies.

An FDA Form 483 cited unaddressed contamination, pest infestations, and equipment failures at manufacturer’s Bloomington, IN facility, which was acquired in the Catalent buyout.

Addressing the most common concerns surrounding the legislation intended to establish interoperability within the pharma supply chain.

The new framework, set to take effect Sept. 1, limits tariffs on pharmaceutical imports to 15% but follows months of shifting proposals, including threats of tariffs as high as 250%.

The company will be heavily investing over the next decade to build a new biopharmaceutical facility in Holly Springs, NC, creating 120 jobs and reinforcing its $55 billion pledge to strengthen US manufacturing, R&D, and innovation.